Kronos Bio, Inc. announced a plan to optimize its resource allocation, restructure, and extend runway to focus resources on key programs in the Company?s pipeline, including the ongoing phase 1/2 study of KB-0742 following the review of additional positive preliminary safety and efficacy data. The company expects these efforts, which include a 21% reduction in force, will extend cash runway into the second half of 2026.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.02 USD | -1.92% | +2.05% | -18.40% |
May. 09 | Earnings Flash (KRON) KRONOS BIO Reports Q1 Revenue $2.52M | MT |
May. 09 | Kronos Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.40% | 62.5M | |
+44.48% | 54.04B | |
+43.57% | 41.96B | |
-0.86% | 41.92B | |
-7.59% | 28.35B | |
+12.30% | 26.35B | |
-21.83% | 19B | |
+7.15% | 13B | |
+29.40% | 12.28B | |
+25.15% | 12.19B |
- Stock Market
- Equities
- KRON Stock
- News Kronos Bio, Inc.
- Kronos Bio Plans to Reduction in Force